An evaluation of the Abbott HBe RIA test has given us the opportunity to survey in detail the distribution of HBeAg and its antibody in our donor population and to consider the possible practical value of tests for 'e' status in blood transfusion practice.
Since the description in 1972 of hepatitis B e antigen (HBeAg) and its antibody (anti-HBe) by Magnius and Espmark' the system has attracted attention because of its apparent clinical significance. Most workers now consider HBeAg to be a marker of infectivity; conversely, in hepatitis B surface antigen (HBsAg) carriers, the presence of anti-HBe may indicate low infectivity.2 Tests for these markers therefore may have important practical uses in transfusion centres for (a) counselling HBsAg positive blood donors, and (b) advising the medical, dental, and nursing professions on the care of these donors.
Previous large-scale reports have tended to describe communities with differing carrier rates of HBsAg from those seen in the United Kingdom. Many of these reports have been based on insensitive tests for HBeAg and anti-HBe with the result that a substantial proportion of donors could not be classified. A sensitive radioimmunoassay (RIA) has been shown to increase the proportion of HBsAg positive sera that may be classified in the HBeAg and anti-HBe system.3 4 An evaluation of the Abbott HBe RIA test has given us the opportunity to survey in detail the distribution of HBeAg and its antibody in our donor population and to consider the possible practical value of tests for 'e' status in blood transfusion practice.
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The sera tested were obtained from 246 HBsAg positive volunteer blood donors in the West of Scotland.
HBsAg was detected by solid-phase radioimmunoassay (RIA, Abbott).
HBeAg and anti-HBe determinations were performed by solid-phase radioimmunoassay (RIA, Abbott). Repeat testing was performed to confirm all positive reactions.
HBsAg subtyping was performed by our micro solid-phase radioimmunoassay. Polystyrene beads of 3-2 mm diameter (Precision Plastic Ball Co, Chicago, III, USA) were coated with guinea-pig monospecific anti-d or anti-y serum. The coated beads were dispensed into the reaction wells of a V-shaped microtitre plate, and 0-1 ml of test serum or plasma was added. Each serum was tested in duplicate against both anti-d and anti-y beads. The plates were sealed and left overnight at 220C. The tests were washed four times with 0 3 ml distilled water, and 0-1 ml human 1251-labelled anti-HBs (Abbott) reacting with both ad and ay subtypes was added. After incubation at 45°C for 1 hour in a water bath, the tests were washed four times and the beads were transferred to counting tubes. Each tube was counted for 1 minute in a gamma counter, and the ratio of test cpm/negative mean cpm was determined. HBsAg subtype ad produced higher ratios with anti-d coated beads compared with anti-y 1106 The higher prevalence of HBeAg among HBsAg carriers under the age of 30 is significant (P < 0-001), and the higher prevalence of anti-HBe among carriers over the age of 30 is significant (P < 0-001).
No association was found between blood group A and the presence or absence of HBeAg or its antibody (Table 1) , although an earlier report by Barr et al.5 suggested that HBeAg might be less common among donors of blood group A than in the general carrier population. The 105 donor samples in the previous report were re-tested in the present study, and the performance of immunodiffusion is compared with that of RIA in Table 2 . All positive immunodiffusion results were confirmed by RIA, but RIA detected both HBeAg and anti-HBe more frequently.
HBeAg was present in 19% of the 211 male donors and in 11 % of the 35 female donors. AntiHBe was found in 79 Y. of the males and in 89% of the females (Table 3 ). The difference is not significant. ,ug/ml of HBsAg were HBeAg positive. The mean UBsAg concentration of samples found to be HBeAg positive was 72 ,ug/ml and anti-HBe positive 17 ,ug/ml, and neither detected 10 ,tg/ml. Although the mean HBsAg concentration in HBeAg positive individuals was four times greater than in those with anti-HBe, it should be noted that HBeAgs were found at other levels of HBsAg concentration, one even as low as 4 ng/ml. Three samples in the panel were from donations that had been involved in post-transfusion hepatitis B cases. All three samples were found to be HBeAg positive.
A follow-up of eight HBeAg positive blood donors has revealed that two donors seroconverted from HBsAg HBeAg to anti-HBs anti-HBe, one donor seroconverted from HBeAg to anti-HBe while remaining HBsAg positive, and the remaining five were still positive for both HBsAg and HBeAg after one to four years.
A follow-up of one of the four donors giving unclassifiable results showed that this donor had seroconverted from HBsAg positive to anti-HBs anti-HBe positive. As the HBsAg concentration of the original sample was 10 ng/ml, it appears that the donor was in the early acute phase of viral hepatitis B at that time.
Discussion
In the whole survey, the percentages of HBeAg and anti-HBe were 18-3 % and 80-1 %, respectively, while 1-6 % were unclassifiable. The unclassified results were in four donors, two of whom had very low levels of HBsAg (less than 10 ng/ml), and were most probably in the early acute phase of viral hepatitis; the other two unclassified results were associated with higher levels of HBsAg and could be explained by these donors being in the process of seroconversion from HBeAg to anti-HBe.
In our population of HBsAg positive donors, HBeAg was present in 29-7 % and anti-HBe in 68y0% of those under the age of 30 years, while in those over 30 years HBeAg was present in 5-9y%
and anti-HBe in 93.2%. This decreasing frequency of HBeAg with age and increasing frequency of anti-HBe with age confirmed earlier reports56 but was in contrast to a French study.7 The reduction in HBeAg with increasing age may be attributed to a tendency of HBeAg positive carriers to seroconvert to anti-HBe or to some progressive change in the clinical and epidemiological pattern of hepatitis B carriage. As such a change could be associated with an increase in hepatitis B among parenteral drug abusers, and as most of the drug-associated hepatitis in our region is of subtype ay,8 we examined markers according to the HBsAg subtype; no difference was found. Moreover, as our results show no difference in the relative numbers of ad and ay carriers between the younger and older age groups, it seems that the drug culture has had little or no impact on our HBsAg carrier blood donor population.
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